Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Trodelvy | sacituzumab govitecan-hziy | Gilead Sciences | N-761115 RX | 2020-04-22 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
trodelvy | Biologic Licensing Application | 2024-09-03 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
triple negative breast neoplasms | — | D064726 | — |
Code | Description |
---|---|
J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 12 | 32 | 9 | — | 5 | 50 |
Triple negative breast neoplasms | D064726 | — | — | 7 | 22 | 6 | — | 2 | 32 |
Carcinoma | D002277 | — | C80.0 | 6 | 15 | 2 | — | — | 20 |
Urinary bladder neoplasms | D001749 | — | C67 | 4 | 8 | 1 | — | 1 | 12 |
Non-small-cell lung carcinoma | D002289 | — | — | 3 | 8 | 2 | — | — | 11 |
Urologic neoplasms | D014571 | — | C64-C68 | 4 | 5 | 2 | — | — | 8 |
Transitional cell carcinoma | D002295 | — | — | 3 | 4 | 2 | — | — | 7 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 5 | 1 | — | — | 7 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 3 | 1 | — | — | 4 |
Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 1 | — | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 4 | — | — | — | 5 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 4 | — | — | — | 5 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 5 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | — | 3 |
Small cell lung carcinoma | D055752 | — | — | 2 | 3 | — | — | — | 3 |
Adenocarcinoma | D000230 | — | — | 2 | 3 | — | — | — | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 3 | — | — | — | 3 |
Neuroendocrine carcinoma | D018278 | — | — | 1 | 3 | — | — | — | 3 |
Squamous cell carcinoma | D002294 | — | — | — | 3 | — | — | — | 3 |
Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver failure | D017093 | HP_0001399 | K72.9 | 1 | — | — | — | — | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
Toxemia | D014115 | — | — | — | — | — | — | 1 | 1 |
Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Sacituzumab govitecan |
INN | sacituzumab govitecan |
Description | Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
|
Classification | Antibody |
Drug class | monoclonal antibodies; antineoplastics (camptothecin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3545262 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12893 |
UNII ID | M9BYU8XDQ6 (ChemIDplus, GSRS) |